17,044 Shares in Beta Bionics, Inc. $BBNX Bought by Nuveen LLC

Key Points

• Nuveen LLC acquired 17,044 shares of Beta Bionics, Inc. valued at approximately $209,000 in the first quarter.
• Beta Bionics reported a quarterly EPS of ($0.39), exceeding analysts' estimates of ($0.51), with revenue of $23.24 million.
• Several research firms have recently rated Beta Bionics, with target prices ranging from $16.00 to $30.00 and a consensus target price of $22.56.

Nuveen LLC acquired a new stake in Beta Bionics, Inc. (NASDAQ:BBNX - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 17,044 shares of the company's stock, valued at approximately $209,000.

Several other institutional investors and hedge funds also recently made changes to their positions in BBNX. Rhumbline Advisers purchased a new stake in shares of Beta Bionics in the first quarter valued at about $158,000. Evanson Asset Management LLC purchased a new position in Beta Bionics during the first quarter valued at approximately $475,000. Bank of New York Mellon Corp bought a new stake in Beta Bionics during the first quarter valued at approximately $316,000. Values First Advisors Inc. bought a new stake in Beta Bionics during the first quarter valued at approximately $457,000. Finally, Jennison Associates LLC bought a new stake in shares of Beta Bionics in the 1st quarter worth approximately $828,000.

Beta Bionics Trading Up 0.5%

NASDAQ BBNX opened at $20.20 on Friday. Beta Bionics, Inc. has a one year low of $8.89 and a one year high of $24.50. The stock has a 50 day moving average price of $15.60 and a 200-day moving average price of $15.09.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported ($0.39) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.12. The firm had revenue of $23.24 million for the quarter, compared to the consensus estimate of $19.73 million. Beta Bionics has set its FY 2025 guidance at EPS.

Wall Street Analyst Weigh In

A number of research firms recently commented on BBNX. The Goldman Sachs Group began coverage on shares of Beta Bionics in a report on Friday, May 30th. They set a "neutral" rating and a $16.00 price target for the company. Wolfe Research began coverage on shares of Beta Bionics in a research report on Friday, May 30th. They issued an "outperform" rating and a $20.00 target price on the stock. Truist Financial upped their target price on shares of Beta Bionics from $18.00 to $21.00 and gave the stock a "buy" rating in a research report on Wednesday, July 30th. Robert W. Baird set a $17.00 target price on shares of Beta Bionics and gave the stock a "neutral" rating in a research report on Wednesday, July 30th. Finally, Lake Street Capital assumed coverage on shares of Beta Bionics in a research note on Thursday, June 12th. They issued a "buy" rating and a $30.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Beta Bionics currently has an average rating of "Moderate Buy" and a consensus target price of $22.56.

Insider Transactions at Beta Bionics

In related news, insider Mark Hopman sold 16,158 shares of Beta Bionics stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $16.61, for a total transaction of $268,384.38. Following the completion of the transaction, the insider directly owned 34,132 shares of the company's stock, valued at approximately $566,932.52. The trade was a 32.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen Feider sold 5,587 shares of the business's stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $17.03, for a total transaction of $95,146.61. Following the sale, the chief financial officer directly owned 45,503 shares of the company's stock, valued at $774,916.09. This represents a 10.94% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,572 shares of company stock valued at $521,844.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.